New immune therapy targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This early-stage trial tests a new treatment made from a patient's own immune cells (TILs) for metastatic colorectal or prostate cancer. The goal is to see if repeated doses are safe and feasible in 12 participants. The therapy aims to help the immune system fight cancer, but ong…
Phase: PHASE1, PHASE2 • Sponsor: CuraCell TX AB • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC